Lithium Inhibits Tumorigenic Potential of PDA Cells through Targeting Hedgehog-GLI Signaling Pathway

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Peng, Zhonglu ^a   Ji, Zhengyu ^b,c   Mei, Fang ^b   Lu, Meiling ^a   Ou, Yu ^a   Cheng, Xiaodong ^b  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b University of Texas Medical Branch School of Medicine   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; LITHIUM CHLORIDE; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR GLI1; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; GLI1 PROTEIN, HUMAN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; PROTEASOME; TRANSCRIPTION FACTOR;

APOPTOSIS; ARTICLE; CARCINOGENICITY; CARCINOMA CELL; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; PANCREAS ADENOCARCINOMA; PROTEIN STABILITY; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; ANALOGS AND DERIVATIVES; CARCINOMA, PANCREATIC DUCTAL; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PANCREATIC NEOPLASMS; PATHOLOGY; PROTEIN DEGRADATION; TUMOR CELL LINE;

ERINACEIDAE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LITHIUM CHLORIDE; PANCREATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84876547331     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061457     Document Type: Article

References (58)

1. Siegel R, Naishadham D, Jemal A, (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
2. Kim R, (2011) FOLFIRINOX: a new standard treatment for advanced pancreatic cancer? Lancet Oncol 12: 8-9.
3. Philip PA, (2008) Improving treatment of pancreatic cancer. Lancet Oncol 9: 7-8.
4. Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, et al. (2009) Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 27: 2231-2237.
5. Van Cutsem E, Verslype C, Grusenmeyer PA, (2007) Lessons learned in the management of advanced pancreatic cancer. J Clin Oncol 25: 1949-1952.
6. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, et al. (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-1966.
7. Hidalgo M, (2010) Pancreatic cancer. N Engl J Med 362: 1605-1617.
8. McMahon AP, Ingham PW, Tabin CJ, (2003) Developmental roles and clinical significance of hedgehog signaling. Curr Top Dev Biol 53: 1-114.
9. Lewis EB, (1978) A gene complex controlling segmentation in Drosophila. Nature 276: 565-570.
10. Zhao Q, Beck A, Fraidenraich D, (2010) A direct, non-canonical pathway for Hedgehog proteins in the endothelium. Cell Cycle 9: 647-648.
11. Blotta S, Jakubikova J, Calimeri T, Roccaro AM, Amodio N, et al. (2012) Canonical and non canonical Hedgehog pathway in the pathogenesis of multiple myeloma. Blood 120: 5002-5013.
12. Berman DM, Karhadkar SS, Maitra A, Montes De Oca R, Gerstenblith MR, et al. (2003) Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 425: 846-851.
13. Xie J, Murone M, Luoh SM, Ryan A, Gu Q, et al. (1998) Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 391: 90-92.
14. Thayer SP, di Magliano MP, Heiser PW, Nielsen CM, Roberts DJ, et al. (2003) Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 425: 851-856.
15. Ji Z, Mei FC, Xie J, Cheng X, (2007) Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells. J Biol Chem 282: 14048-14055.
16. Wang Y, Ding Q, Yen CJ, Xia W, Izzo JG, et al. (2012) The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell 21: 374-387.
17. Xu X, Zhou Y, Xie C, Wei SM, Gan H, et al. (2012) Genome-Wide Screening Reveals an EMT Molecular Network Mediated by Sonic Hedgehog-Gli1 Signaling in Pancreatic Cancer Cells. PLoS One 7: e43119.
18. Soleti R, Benameur T, Porro C, Panaro MA, Andriantsitohaina R, et al. (2009) Microparticles harboring Sonic Hedgehog promote angiogenesis through the upregulation of adhesion proteins and proangiogenic factors. Carcinogenesis 30: 580-588.
19. Nolan-Stevaux O, Lau J, Truitt ML, Chu GC, Hebrok M, et al. (2009) GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes Dev 23: 24-36.
20. Mazumdar T, (2011) The GLI genes as the molecular switch in disrupting Hedgehog signaling in colon cancer. oncotarget 2: 638-645.
21. Lauth M, Bergstrom A, Shimokawa T, Toftgard R, (2007) Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci U S A 104: 8455-8460.
22. Johnson G, Gershon S, (1999) Early North American research on lithium. Aust N Z J Psychiatry 33Suppl: S48-53.
23. Cohen P, Goedert M, (2004) GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov 3: 479-487.
24. Klein PS, Melton DA, (1996) A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A 93: 8455-8459.
25. Mora A, Sabio G, Risco AM, Cuenda A, Alonso JC, et al. (2002) Lithium blocks the PKB and GSK3 dephosphorylation induced by ceramide through protein phosphatase-2A. Cell Signal 14: 557-562.
26. Quiroz JA, Gould TD, Manji HK, (2004) Molecular effects of lithium. Mol Interv 4: 259-272.
27. Spiegelberg BD, (2005) Alteration of Lithium Pharmacology through Manipulation of Phosphoadenosine Phosphate Metabolism. J Biol Chem 280: 5400-5405.
28. Freland L, Beaulieu JM, (2012) Inhibition of GSK3 by lithium, from single molecules to signaling networks. Front Mol Neurosci 5: 14.
29. Nowicki MO, Dmitrieva N, Stein AM, Cutter JL, Godlewski J, et al. (2008) Lithium inhibits invasion of glioma cells; possible involvement of glycogen synthase kinase-3. Neuro Oncol 10: 690-699.
30. Vidal F, de Araujo WM, Cruz AL, Tanaka MN, Viola JP, et al. (2011) Lithium reduces tumorigenic potential in response to EGF signaling in human colorectal cancer cells. Int J Oncol 38: 1365-1373.
31. Ronchi A, Salaroli R, Rivetti S, Della Bella E, Di Tomaso T, et al. (2011) Lithium induces mortality in medulloblastoma cell lines. Int J Oncol 37: 745-752.
32. Erdal E, Ozturk N, Cagatay T, Eksioglu-Demiralp E, Ozturk M, (2005) Lithium-mediated downregulation of PKB/Akt and cyclin E with growth inhibition in hepatocellular carcinoma cells. Int J Cancer 115: 903-910.
33. Beyaert R, Vanhaesebroeck B, Suffys P, Van Roy F, Fiers W, (1989) Lithium chloride potentiates tumor necrosis factor-mediated cytotoxicity in vitro and in vivo. Proc Natl Acad Sci U S A 86: 9494-9498.
34. Cohen Y, Chetrit A, Cohen Y, Sirota P, Modan B, (1998) Cancer morbidity in psychiatric patients: influence of lithium carbonate treatment. Med Oncol 15: 32-36.
35. Zhu Z, Kremer P, Tadmori I, Ren Y, Sun D, et al. (2011) Lithium suppresses astrogliogenesis by neural stem and progenitor cells by inhibiting STAT3 pathway independently of glycogen synthase kinase 3 beta. PLoS One 6: e23341.
36. Kaufmann L, Marinescu G, Nazarenko I, Thiele W, Oberle C, et al. (2011) LiCl induces TNF-alpha and FasL production, thereby stimulating apoptosis in cancer cells. Cell Commun Signal 9: 15.
37. Mao CD, Hoang P, DiCorleto PE, (2001) Lithium inhibits cell cycle progression and induces stabilization of p53 in bovine aortic endothelial cells. J Biol Chem 276: 26180-26188.
38. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, et al. (1988) Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53: 549-554.
39. Levy L, Hill CS, (2005) Smad4 dependency defines two classes of transforming growth factor {beta} (TGF-{beta}) target genes and distinguishes TGF-{beta}-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses. Mol Cell Biol 25: 8108-8125.
40. Kayed H, Kleeff J, Osman T, Keleg S, Buchler MW, et al. (2006) Hedgehog signaling in the normal and diseased pancreas. Pancreas 32: 119-129.
41. Chen JK, (2002) Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes & Development 16: 2743-2748.
42. Daniel D. Von Hoff MD, Patricia M LoRusso, D.O., et al, (2009) Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma. N Engl J Med 361: 1164-1172.
43. Merchant AA, Matsui W, (2010) Targeting Hedgehog - a Cancer Stem Cell Pathway. Clinical Cancer Research 16: 3130-3140.
44. Low JA, de Sauvage FJ, (2010) Clinical experience with Hedgehog pathway inhibitors. J Clin Oncol 28: 5321-5326.
45. Fu J, Rodova M, Roy SK, Sharma J, Singh KP, et al. (2013) GANT-61 inhibits pancreatic cancer stem cell growth in vitro and in NOD/SCID/IL2R gamma null mice xenograft. Cancer Lett 330: 22-32.
46. Huntzicker EG, Estay IS, Zhen H, Lokteva LA, Jackson PK, et al. (2006) Dual degradation signals control Gli protein stability and tumor formation. Genes Dev 20: 276-281.
47. Jiang J, (2006) Regulation of Hh/Gli signaling by dual ubiquitin pathways. Cell Cycle 5: 2457-2463.
48. Plyte SE, Hughes K, Nikolakaki E, Pulverer BJ, Woodgett JR, (1992) Glycogen synthase kinase-3: functions in oncogenesis and development. Biochim Biophys Acta 1114: 147-162.
49. Kotliarova S, Pastorino S, Kovell LC, Kotliarov Y, Song H, et al. (2008) Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. Cancer Res 68: 6643-6651.
50. Marchand B, Tremblay I, Cagnol S, Boucher MJ, (2012) Inhibition of glycogen synthase kinase-3 activity triggers an apoptotic response in pancreatic cancer cells through JNK-dependent mechanisms. Carcinogenesis 33: 529-537.
51. Shimasaki T, Ishigaki Y, Nakamura Y, Takata T, Nakaya N, et al. (2012) Glycogen synthase kinase 3beta inhibition sensitizes pancreatic cancer cells to gemcitabine. J Gastroenterol 47: 321-333.
52. Schotte P, Van Loo G, Carpentier I, Vandenabeele P, Beyaert R, (2001) Lithium sensitizes tumor cells in an NF-kappa B-independent way to caspase activation and apoptosis induced by tumor necrosis factor (TNF). Evidence for a role of the TNF receptor-associated death domain protein. J Biol Chem 276: 25939-25945.
53. Welsh GI, Miller CM, Loughlin AJ, Price NT, Proud CG, (1998) Regulation of eukaryotic initiation factor eIF2B: glycogen synthase kinase-3 phosphorylates a conserved serine which undergoes dephosphorylation in response to insulin. FEBS Lett 421: 125-130.
54. Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, et al. (2006) TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126: 955-968.
55. Sun A, Shanmugam I, Song J, Terranova PF, Thrasher JB, et al. (2007) Lithium suppresses cell proliferation by interrupting E2F-DNA interaction and subsequently reducing S-phase gene expression in prostate cancer. Prostate 67: 976-988.
56. Welcker M, Singer J, Loeb KR, Grim J, Bloecher A, et al. (2003) Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation. Mol Cell 12: 381-392.
57. Regl G, Kasper M, Schnidar H, Eichberger T, Neill GW, et al. (2004) The zinc-finger transcription factor GLI2 antagonizes contact inhibition and differentiation of human epidermal cells. Oncogene 23: 1263-1274.
58. Sasaki H, Hui C, Nakafuku M, Kondoh H, (1997) A binding site for Gli proteins is essential for HNF-3beta floor plate enhancer activity in transgenics and can respond to Shh in vitro. Development 124: 1313-1322.